Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease

OBJECTIVES: Inflammatory rheumatic and musculoskeletal diseases (iRMDs) are associated with increased systemic bone loss that is mediated by chronic inflammation, treatment with glucocorticoids (GCs) and other factors. Our objective was to analyse the impact of variables that influence osteoporosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiebe, Edgar, Huscher, Dörte, Schaumburg, Désireé, Palmowski, Andriko, Hermann, Sandra, Buttgereit, Thomas, Biesen, Robert, Burmester, Gerd-Rüdiger, Palmowski, Yannick, Boers, Maarten, Stone, John H, Dejaco, Christian, Buttgereit, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Osteoporosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380479/
https://www.ncbi.nlm.nih.gov/pubmed/35680387
http://dx.doi.org/10.1136/annrheumdis-2022-222339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380479/
https://www.ncbi.nlm.nih.gov/pubmed/35680387
http://dx.doi.org/10.1136/annrheumdis-2022-222339

Ejemplares similares